Bredella Miriam A, Karastergiou Kalypso, Bos Stijn A, Gerweck Anu V, Torriani Martin, Fried Susan K, Miller Karen K
Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Department of Medicine, Section of Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, 650 Albany St., EBRC 810, Boston, MA 02118, United States.
Growth Horm IGF Res. 2017 Aug;35:17-20. doi: 10.1016/j.ghir.2017.06.001. Epub 2017 Jun 12.
To investigate the effects of short-term GH administration on abdominal subcutaneous adipocyte size and CT attenuation in men with abdominal obesity.
6-week, randomized, double-blind, placebo-controlled study of GH (starting dose 2μg/kg/d) vs placebo of 15 abdominally obese men (mean age: 34±6years; mean BMI: 37.7±6.1kg/m, mean IGF-1 SDS: -1.9±0.5) who underwent abdominal subcutaneous adipose tissue (SAT) aspirations to determine adipocyte size, CTs for body composition and measures of glucose tolerance at baseline and 6weeks. GH dosing was titrated to target IGF-1 levels in the upper normal age-appropriate range.
GH administration decreased subcutaneous abdominal adipocyte size compared to placebo. Adipocyte size was positively associated with 120-min glucose and HOMA-IR and inversely associated with peak-stimulated GH and CT attenuation. CT attenuation of SAT was inversely associated with 120-min glucose and HOMA-IR and increased following GH administration.
In men with abdominal obesity, subcutaneous abdominal adipocyte size is positively associated with measures of impaired glucose tolerance and administration of GH at doses that raise IGF-1 levels within the normal range, decreases abdominal subcutaneous adipocyte size, suggesting that GH administration improves the health of adipose tissue. Clinical trials number: NCT00131378.
研究短期给予生长激素（GH）对腹部肥胖男性腹部皮下脂肪细胞大小及CT衰减值的影响。
一项为期6周的随机、双盲、安慰剂对照研究，15名腹部肥胖男性（平均年龄：34±6岁；平均体重指数：37.7±6.1kg/m²，平均胰岛素样生长因子-1标准差分值：-1.9±0.5）参与，比较GH（起始剂量2μg/kg/d）与安慰剂的效果。这些男性接受腹部皮下脂肪组织（SAT）抽吸以确定脂肪细胞大小，进行身体成分CT扫描，并在基线和6周时测量葡萄糖耐量。GH剂量根据目标胰岛素样生长因子-1水平进行滴定，使其处于适合年龄的正常上限范围内。
与安慰剂相比，给予GH可减小腹部皮下脂肪细胞大小。脂肪细胞大小与120分钟血糖及胰岛素抵抗稳态模型评估（HOMA-IR）呈正相关，与峰值刺激GH及CT衰减值呈负相关。SAT的CT衰减值与120分钟血糖及HOMA-IR呈负相关，给予GH后增加。
在腹部肥胖男性中，腹部皮下脂肪细胞大小与葡萄糖耐量受损指标呈正相关，给予能使胰岛素样生长因子-1水平升高至正常范围的剂量的GH，可减小腹部皮下脂肪细胞大小，这表明给予GH可改善脂肪组织健康。临床试验编号：NCT00131378。
